Wang Rosi, Mathes Sonja, Claussen Carla, Biedermann Tilo, Brockow Knut
Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.
J Dtsch Dermatol Ges. 2023 Mar;21(3):255-262. doi: 10.1111/ddg.14987. Epub 2023 Mar 9.
Cutaneous reactions following COVID-19 vaccination have been frequently described, whereas larger case series by dermatologists are lacking. This study assesses SARS-CoV-2 vaccination-associated skin reactions, severity, treatment, course, eliciting vaccines, allergy test results and tolerance to revaccination.
Single-institutional, non-interventional study of dermatologists assessing cutaneous manifestations in 83 patients in Germany.
93 reactions were presented. Manifestations clustered into immediate (n = 51, 54.8%) and delayed hypersensitivity reactions (n = 10, 10.8%), chronic inflammatory skin diseases (n = 13, 14.0%), reactivation of latent herpes virus infection (pityriasis rosea/herpes zoster; n = 9; 9.7%) and others (n = 10, 10.8%). Vaccination was associated with new (76.3%) - mostly hypersensitivity reactions - or exacerbation of known skin diseases (23.7%), in this case predominantly chronic inflammatory skin diseases. Reactions occurred primarily within the first week (72.8%) and after first vaccination (62.0%). Treatment was required in 83.9% and hospitalization in 19.4%. In 48.8% revaccination led to recurrence of the same reactions. Disease was ongoing at last consultation in 22.6%, primarily in chronic inflammatory skin diseases. Allergy tests were performed in 15 patients (18.1%) and resulted negative.
It can be assumed that vaccination may trigger immune activation-related reactions especially in those patients predisposed to develop respective skin diseases.
新冠病毒疫苗接种后的皮肤反应已有诸多报道,但皮肤科医生开展的大规模病例系列研究尚缺。本研究评估了与接种严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗相关的皮肤反应、严重程度、治疗、病程、引发反应的疫苗、过敏试验结果及再次接种的耐受性。
德国一家机构的皮肤科医生开展的单中心、非干预性研究,评估了83例患者的皮肤表现。
共出现93例反应。表现分为速发型(n = 51,54.8%)和迟发型超敏反应(n = 10,10.8%)、慢性炎症性皮肤病(n = 13,14.0%)、潜伏性疱疹病毒感染再激活(玫瑰糠疹/带状疱疹;n = 9;9.7%)及其他(n = 10,10.8%)。疫苗接种与新发(76.3%)——主要是超敏反应——或已知皮肤病加重(23.7%)相关,在这种情况下主要是慢性炎症性皮肤病。反应主要发生在第一周内(72.8%)和首次接种后(62.0%)。83.9%的患者需要治疗,19.4%的患者需要住院。48.8%的患者再次接种导致相同反应复发。在最后一次会诊时疾病仍在持续的患者占22.6%,主要是慢性炎症性皮肤病。15例患者(18.1%)进行了过敏试验,结果均为阴性。
可以推测,疫苗接种可能引发与免疫激活相关的反应,尤其是在那些易患相应皮肤病的患者中。